arrow
A

Andrew Haydon

the alfred hospital
H指数:57
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Processed meat, unprocessed red meat, poultry, seafood, and egg intake and stomach cancer risk: a pooled analysis of 20 cohorts

加工肉类、未加工红肉、禽肉、海产品和鸡蛋摄入与胃癌风险:一项20项队列研究的合并分析

2026-01-010
PRE
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults

非甾体抗炎药物及阿司匹林与老年人群结直肠癌发病率的关联

2025-07-010
OAAI
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors

评估免疫检查点抑制剂治疗后慢性皮肤免疫相关不良事件的特征

2025-05-010
PRE
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

EORTC1325/KEYNOTE-054试验中pembrolizumab与安慰剂在III期黑色素瘤中的七年分析

2024-11-012
PRE
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
2024-11-010
PRE
Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial

帕博利珠单抗与安慰剂用于高危III期黑色素瘤完全切除后的治疗:EORTC 1325-MG/Keynote-054 III期双盲试验7年结果

2024-09-010
PRE
Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial

从结直肠癌手术到辅助化疗的时间SCOT随机临床试验的事后分析

2024-08-011
PRE
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after de fi nitive surgery: a multicenter, retrospective cohort study (vol 65, 102290, 2023)

Dabrafenib联合曲美替尼与anti-PD-1单药治疗BRAF V600-mutant III期黑色素瘤术后的辅助治疗: 一项多中心,回顾性队列研究 (第65卷,102290,2023)

2024-05-010
OAAI
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*

非甾体抗炎药在EORTC 1325/KEYNOTE-054 pembrolizumab与安慰剂在切除的高风险III期黑色素瘤中的预后和预测价值 *

2024-04-010
PRE
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

基于辅助PD-1的免疫治疗后复发黑色素瘤局部治疗后使用BRAF/MEK抑制剂的 “第二佐剂” 治疗的疗效和安全性

2024-03-014
PRE
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (vol 29, pg 3100, 2023)
2024-01-032
OA
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
2024-01-012
PRE
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis (oct, 10.1038/s41591-023-02591-2, 2023)
2023-11-270
OA
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Dabrafenib联合曲美替尼与anti-PD-1单药治疗BRAF V600-mutant III期黑色素瘤确定性手术后的辅助治疗: 一项多中心,回顾性队列研究

2023-11-017
OAAI
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) plus binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
2023-11-012
PRE